GSK Consumer Healthcare and Pfizer Complete Organizational Structure for Joint Venture Ahead of IPO

Recently, the organizational structure of the new company formed by the merger of GSK Consumer Healthcare and Pfizer’s Consumer Healthcare Business Unit was announced. In the Asia-Pacific region, responsibility remains with Cai Baoguang, former President of Pfizer Asia Pacific. Gu Haiying, former General Manager of Pfizer’s Consumer Healthcare Business Unit in China, has been appointed as General Manager for Greater China at the new company.

On December 19, 2018, Pfizer and GlaxoSmithKline separately announced that they had reached an agreement to merge their consumer healthcare businesses. The new company would operate globally under the name GSK Consumer Healthcare, meaning Pfizer’s Consumer Healthcare division would be integrated into GlaxoSmithKline’s Consumer Healthcare business.

The newly merged GSK Consumer Healthcare company will achieve global sales of $12.7 billion, with GSK holding a majority stake of 68% and Pfizer holding a 32% joint venture equity interest. GSK CEO Emma Walmsley will serve as Chair of the Board, while Pfizer has the right to appoint three of the nine board members. Additionally, Brian McNamara, CEO of GSK Consumer Healthcare, and Simon Dingemans, CFO, will continue to serve as CEO and CFO of the new joint venture, respectively.

On March 18 this year, Brian McNamara, CEO of the new GSK Consumer Healthcare company, announced the appointment of the leadership team for the company’s health medicines division. Baoguang Cai, former President of International Markets at Pfizer Consumer Healthcare (PCH), and Chris Slage have joined the new leadership team, overseeing the Asia-Pacific and U.S. regions, respectively.